Sanofi opens digital biologics manufacturing facility in US

The facility in Framingham accelerates the recent transformation of Sanofi's Industrial Affairs organization to focus on biologics-based therapies, in line with the transformation of the company's RnD pipeline, Sanofi said.

New Delhi: Sanofi recently celebrated the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using intensified, continuous biologics production technology.

The new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialization of important new medicines for patients.

In a press release, Sanofi said this facility accelerates the recent transformation of Sanofi's Industrial Affairs organization to focus on biologics-based therapies, in line with the transformation of the company's R&D pipeline. The ramping up of biopharmaceutical production capacities is a key pillar to achieving Sanofi's ambition to establish the gold standard in the biopharmaceutical industry.

The facility's advanced paperless and data-driven manufacturing technologies is expected to enable Sanofi to achieve higher levels of productivity, agility, and flexibility, reducing the time it takes for products to move from the development labs to the manufacturing plant, and – most importantly – meeting the needs of patients around the world.

Also Read: Sanofi India sells the oldest facility at Ankleshwar to Advent for Rs 262 crore

Commenting on the same, Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi said, "We have been investing for some years to prepare for Sanofi's future. Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility."

"This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry, " Luscan added.

The digital transformation of Sanofi's manufacturing network is a key element of the company's goal to leverage better use of data to optimize the company's manufacturing processes, increasing efficiencies, improving the agility needed to respond to fast-changing patient needs, and speeding up the commercialization of new medicines emerging from the R&D pipeline.

Framingham is the latest biologics manufacturing facility amongst a number of pilots, which are being accelerated across the Sanofi network. The innovations established at this facility are being rapidly deployed and standardized across the company. Framingham is the first "digitally born" facility while similar digital transformations are introduced in other legacy plants. Beyond Framingham, Sanofi intends to move forward with digital transformation initiatives in Toronto (Canada), Suzano (Brazil), Waterford (Ireland), Sisteron (France), and Geel (Belgium).

The Framingham digital bio-manufacturing facility is part of Sanofi's integrated, cross-functional biologics hub in Framingham, Massachusetts. A critical global hub for more than 30 years, the campus offers co-location of all the infrastructure and activities required to speed the delivery of innovative new therapies to patients, from early-stage research and process development through clinical and commercial manufacturing, including the key enabling functions of quality control and compliance, regulatory, engineering, supply chain, and learning and development.

The co-location of these critical functions allows for seamless, end-to-end product and process design and manufacturing and provides leading-edge development opportunities for our employees' competencies evolution.

Also Read: Sanofi revival depends on outsider with nose for big drugs: Report